HopeStage
Back to all studies
CompletedNCT05053503

Ear-based nerve stimulation alongside naltrexone for opioid relapse prevention

About this titleRead the official source — NCT05053503
Medication studyAges 18–65United StatesAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
Rancho Mirage and 3 more locationsSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: May 27, 2022
Recruitment status
Completed
Enrollment listed in the registry
108
Sponsor
Spark Biomedical, Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Device, Drug
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT05053503
Official title
Show the full official title

Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Rancho Mirage · Crownsville · Center City

1 more locations
  • Plymouth

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Spark Biomedical, Inc.

Did this study involve medication?

Yes. The study involved medication, including Lofexidine and Extended-release injectable naltrexone.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies